Abstract Library

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,

#2160 A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)

Introduction: SSAs are recommended for the treatment of locoregional/metastatic NET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Klink A, Feinberg B, Yu H, Ray D, Pulgar S,

Keywords: neuroendocrine tumors, somatostatin analogues, lanreotide, octreotide, carcinoid syndrome,

#1940 Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Introduction: The tryptophan hydroxylase inhibitor telotristat ethyl (TE) significantly reduced bowel movement (BM) frequency versus placebo (pbo) in patients (pts) with carcinoid syndrome (CS) in the TELESTAR study.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Anthony L, Kulke M, Hörsch D, Bergsland E, Öberg K,

Keywords: serotonin, diarrhea ,

#1798 Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study

Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Dromain C, Majdi A, Houchard A,

Keywords: Lanreotide, dosing interval,

#1385 The Efficiency of Sunitinib in Chinese Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumor

Introduction: Systemic therapies for advanced Pancreatic neuroendocrine tumors (pNETs) are various. Sunitinib has shown its efficiency in pNET in clinical trials. While the efficiency of sunitinib in Chinese pNETs has not reported yet.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gao H

Authors: Gao H, Cheng Y, Bai C,

Keywords: sunitinib, Chinese, pNET, efficiency,